Macquarie Group’s Tvardi Therapeutics TVRD Stock Holding History

Macquarie Group’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-66	Closed	-$614	–	1945
2024 Q2	$614	Buy	+66	New	+$1.57K	﹤0.01%	1868
2022 Q4	–	Sell	-27	Closed	-$14K	–	2162
2022 Q3	$14K	Sell	27 -14	-34%	-$5.07K	﹤0.01%	2303
2022 Q2	$14K	Hold	41	–	–	﹤0.01%	2396
2022 Q1	$18	Hold	41	–	–	﹤0.01%	2420
2021 Q4	$18K	Hold	41	–	–	﹤0.01%	2424
2021 Q3	$23K	Buy	41 +27	+193%	+$13.5K	﹤0.01%	2431
2021 Q2	$7K	Hold	14	–	–	﹤0.01%	2509
2021 Q1	$11K	Sell	14 -7	-33%	-$4.79K	﹤0.01%	2384
2020 Q4	$11K	Hold	21	–	–	﹤0.01%	2301
2020 Q3	$10K	Hold	21	–	–	﹤0.01%	2285
2020 Q2	$13K	Buy	+21	New	+$11.6K	﹤0.01%	2257

Other funds holding TVRD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Macquarie Group's TVRD Position: Q3 2024 in Review

Macquarie Group sold out of Tvardi Therapeutics (TVRD) in Q3 2024, closing a stake of 66 shares — an estimated $614 sold.

Macquarie Group first reported a position in TVRD in Q2 2020 and held it in 11 quarters. The position peaked at $23K in Q3 2021. 69 funds tracked by Wall St. Rank hold TVRD as of Q3 2024.

Macquarie Group reported no remaining Tvardi Therapeutics position as of Q3 2024 after selling out during the quarter.
Macquarie Group sold 66 Tvardi Therapeutics shares in Q3 2024, an estimated $614.
Macquarie Group first reported a position in Tvardi Therapeutics in Q2 2020 and held it in 11 quarters.
Macquarie Group's Tvardi Therapeutics position peaked at $23K in Q3 2021.
69 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2024.

Based on Macquarie Group's 13F filing for Q3 2024, filed 14 Nov 2024.